Boston, United States
Boston, United States

Time filter

Source Type

News Article | February 21, 2017
Site: www.eurekalert.org

Modern houses -- with metal roofs and finished walls--are associated with a more than 9 percent reduction in the odds of malaria in children in sub-Saharan Africa when compared to more traditional thatched houses, according to a study published in PLOS Medicine by Lucy Tusting of the University of Oxford, UK, and colleagues at the London School of Hygiene & Tropical Medicine, UK, Durham University, UK, and the University of Southampton, UK. Insecticide-treated bednets and house spraying have been effective in reducing the prevalence of malaria since the turn of the 21st century, but other approaches are needed for sustainable elimination of the mosquito-transmitted, parasitic disease. Some evidence has suggested that modern houses may protect against the parasite but few studies have rigorously evaluated the association between improved housing and malaria risk. In the new work, researchers analyzed data on malaria prevalence and housing using data collected in 29 surveys carried out in 21 African countries between 2008 and 2015. Information on malaria status -- as tested using a blood smear or rapid test -- was available for 139,318 children under age 5 living in 84,153 households. The proportion of children with malaria detectable in their blood varied by survey, ranging from 0.4% to 45.5% among children living in modern houses and from 0.4% to 70.6% among children living in traditional homes. Across all surveys, modern housing was associated with a 9% to 14% reduction in the odds of malaria infection, after controlling for household wealth and use of insecticides. By comparison, children sleeping under insecticide-treated bednets had a 15% to 16% reduction in odds of testing positive for the disease. Lead author Lucy Tusting from the University of Oxford, said: "Good housing is a core pillar of public health, but is not used widely for malaria control. Well-built housing can block mosquitoes from entering homes and prevent them from transmitting malaria to the people who live there. "This is the first study to compare housing and insecticide-treated nets for malaria control across a range of countries in sub-Saharan Africa. Our study suggests good housing could be an important tool in tackling malaria. This is a welcome finding at a time when we are facing increasing resistance to our most effective insecticides and drugs. We now need to assess the impact of housing improvements on malaria in field trials and to work with architects and urban planners to incorporate protective designs into housing in regions at risk of malaria." The authors note that the effectiveness of improving housing will vary depending on the location. While many mosquitoes enter homes to bite humans at night, outdoor malaria transmission is more common in some places, meaning interventions centered on the home will have less impact. LST is a Skills Development Fellow (#N011570) jointly funded by the UK Medical Research Council and the UK Department for International Development under the MRC/DFID Concordat agreement. PWG is a Career Development Fellow (#K00669X) jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement, also part of the EDCTP2 programme supported by the European Union, and receives support from the Bill and Melinda Gates Foundation (#OPP1068048, #OPP1106023, #OPP1132415). AJT is supported by funding from NIH/NIAID (U19AI089674) , the Bill & Melinda Gates Foundation (OPP1106427, 1032350, OPP1134076, OPP1094793) , the Wellcome Trust (106866/Z/15/Z) and the Clinton Health Access Initiative . SWL is supported by the Global Health Trials funded by the MRC-DfID-Wellcome Trust, and The Bill & Melinda Gates Foundation (OPP1053338). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors have declared that no competing interests exist. Tusting LS, Bottomley C, Gibson H, Kleinschmidt I, Tatem AJ, Lindsay SW, et al. (2017) Housing Improvements and Malaria Risk in Sub-Saharan Africa: A Multi-Country Analysis of Survey Data. PLoS Med 14(2): e1002234. doi:10.1371/journal.pmed.1002234 Oxford Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, United Kingdom Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom School of Health Sciences, University of Witwatersrand, Johannesburg, South Africa WorldPop, Department of Geography and Environment, University of Southampton, Southampton, United Kingdom Flowminder Foundation, Stockholm, Sweden, 7 Department of Biosciences, Durham University, Durham, United Kingdom IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER: http://journals.


News Article | December 2, 2016
Site: www.prnewswire.co.uk

bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, hat sein neueste Produkt, den INSTI HIV-Selbsttest, bei den Mitgliedern des Apothekenbundes von Kenia eingeführt. bioLytical wurde durch die Clinton Health Access Initiative (CHAI) und die Kenya Pharmaceutical Association (KPA) eingeladen, seinen INSTI HIV-Selbsttest vor 350 Apotheken-Vertretern in Nairobi und Mombasa, Kenia einzuführen. CHAI koordiniert eine innovative HIV-Selbsttest-Initiative, mit der HIV-Selbsttests mit geringen Kosten in die Apotheken in Kenia gebracht werden sollen. Der INSTI HIV-Selbsttest war der einzige auf Blut basierende Selbsttest, der aufgrund seiner einzigartigen Eigenschaften und seiner charakteristischen Leistung eingeladen wurde. Rick Galli, bioLyticals Technikleiter, reiste nach Kenia, um sich vor der Programmeinführung mit KPA-Delegierten zu treffen. "Kenia führt auf dem Weg zu HIV-Selbsttests im Subsahara-Afrika über den privaten Sektor", sagte Galli. "bioLytical freut sich sehr über seine Führungsrolle in dieser bahnbrechenden Initiative, die zeigen wird, wie ein gut zugängliches HIV-Selbsttestprogramm mit geringen Kosten effektiv und für Menschen befähigend sein kann, die ihre Gesundheit kontrollieren wollen." Mit einem Netzwerk von über 7000 regulierten Apotheken in ganz Kenia wird diese neue Initiative Zugang zu HIV-Tests liefern, die für die meisten Kenianer im ganzen Land bezahlbar und in lokalen Apotheken erhältlich sind, die ein wichtiger Teil des Gesundheitssystems sind. Das kenianische HIV-Selbsttestprogramm wird nicht nur die Verteilung von HIV-Tests einbeziehen, sondern auch ein Unterstützungsnetzwerk mit Verbindungen zu Pflegeeinrichtungen für Menschen, die positiv testen. Als erstes Testwerkzeug soll der INSTI HIV-Selbsttest Individuen identifizieren, die möglicherweise HIV-infiziert sind, und sie anweisen, so schnell wie möglich in eine Klinik zu gehen, um den Test zu bestätigen und Ratschläge zur Verhütung und Behandlung zu bekommen. Für diejenigen, die negativ testen, ist der Selbsttest eine stärkende Gelegenheit, ihre Verhütungsmethoden in die Hand zu nehmen und HIV-negativ zu bleiben. "Damit ein derartiges neues Programm erfolgreich wird, ist es sehr wichtig, dass richtige Beratung mit Verbindungsaspekten erteilt wird", sagte Galli. "Wir arbeiten mit CHAI, KPA und anderen Interessengruppen in Kenia zusammen, damit Menschen, die den INSTI HIV-Selbsttest anwenden, entsprechend informiert werden, wie und wo sie nach dem Test die benötigte Unterstützung bekommen." bioLytical Laboratories Inc. ist ein kanadisches Unternehmen in privater Hand, das sich im Bereich der Erforschung, Entwicklung und Kommerzialisierung schneller medizinischer In Vitro-Diagnosegeräte am Pflegeort unter Verwendung seiner geschützten INST-Technologieplattform engagiert. Mit weltweiten Genehmigungen durch Regulierungsbehörden, u. a. durch die US-FDA und Health Canada sowie die CE-Kennzeichnung, vermarktet und verkauft bioLytical seine INSTI-HIV-Tests weltweit und seine INSTI HIV/Syphilis-Multiplex-Tests in Europa. Die INSTI-Produktlinie bietet hochgenaue Testergebnisse in 60 Sekunden oder weniger - wesentlich schneller als die 15 bis 20 Minuten, die bei Tests von Mitbewerbern auf Basis der Lateral-Flow-Technik nötig sind. bioLytical verfügt über ein aktives F&E-Programm mit einer Pipeline, zu der unter anderem Tests für Krankheiten wie Zika, Denguefieber, Chikungunyafieber, Hepatitis C und Ebola gehören. Das Unternehmen stellt auch Vertragsdienstleistungen zur Verfügung, im Rahmen derer die INSTI-Plattform angepasst wird, um maßgeschneiderte Lösungen für die funktionalen und technischen Diagnosetestanforderungen anzubieten. Für weitere Informationen besuchen Sie bitte http://www.biolytical.com.


Cohen J.M.,Clinton Health Access Initiative | Woolsey A.M.,Clinton Health Access Initiative | Sabot O.J.,Clinton Health Access Initiative | Gething P.W.,University of Oxford | And 2 more authors.
Science | Year: 2012

Better targeting of antimalarials to people who need them will maximize the impact of interventions in the private sector.


Ajose O.,Clinton Health Access Initiative | Mookerjee S.,Imperial College London | Mills E.J.,University of Ottawa | Boulle A.,University of Cape Town | And 2 more authors.
AIDS | Year: 2012

Background: A growing proportion of patients on antiretroviral therapy in resource-limited settings have switched to second-line regimens. We carried out a systematic review in order to summarize reported rates and reasons for virological failure among people on second-line therapy in resource-limited settings. Methods: Two reviewers independently searched four databases and three conference websites. Full text articles were screened and data extracted using a standardized data extraction form. Results: We retrieved 5812 citations, of which 19 studies reporting second-line failure rates in 2035 patients across low-income and middle-income countries were eligible for inclusion. The cumulative pooled proportion of adult patients failing virologically was 21.8, 23.1, 26.7 and 38.0% at 6, 12, 24 and 36 months, respectively. Most studies did not report adequate information to allow discrimination between drug resistance and poor adherence as reasons for virological failure, but for those that did poor adherence appeared to be the main driver of virological failure. Mortality on second-line was low across all time points. Conclusion: Rates of virological failure on second-line therapy are high in resource-limited settings and associated with duration of exposure to previous drug regimens and poor adherence. The main concern appears to be poor adherence, rather than drug resistance, from the limited number of studies accessing both factors. Access to treatment options beyond second-line remains limited and, therefore, a cause for a concern for those patients in whom drug resistance is the identified cause of virological failure. © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins.


Crawford K.W.,Johns Hopkins University | Crawford K.W.,Us Military Hiv Research Program | Ripin D.H.B.,Clinton Health Access Initiative | Levin A.D.,Clinton Health Access Initiative | And 2 more authors.
The Lancet Infectious Diseases | Year: 2012

It is expected that funding limitations for worldwide HIV treatment and prevention in resource-limited settings will continue, and, because the need for treatment scale-up is urgent, the emphasis on value for money has become an increasing priority. The Conference on Antiretroviral Drug Optimization-a collaborative project between the Clinton Health Access Initiative, the Johns Hopkins University School of Medicine, and the Bill & Melinda Gates Foundation-brought together process chemists, clinical pharmacologists, pharmaceutical scientists, physicians, pharmacists, and regulatory specialists to explore strategies for the reduction of antiretroviral drug costs. The antiretroviral drugs discussed were prioritised for consideration on the basis of their market impact, and the objectives of the conference were framed as discussion questions generated to guide scientific assessment of potential strategies. These strategies included modifications to the synthesis of the active pharmaceutical ingredient (API) and use of cheaper sources of raw materials in synthesis of these ingredients. Innovations in product formulation could improve bioavailability thus needing less API. For several antiretroviral drugs, studies show efficacy is maintained at doses below the approved dose (eg, efavirenz, lopinavir plus ritonavir, atazanavir, and darunavir). Optimising pharmacoenhancement and extending shelf life are additional strategies. The conference highlighted a range of interventions; optimum cost savings could be achieved through combining approaches. © 2012 Elsevier Ltd.


bioLytical Laboratories, l'un des principaux fabricants mondiaux de tests de dépistage rapide des maladies infectieuses, a présenté le tout dernier produit de la société, l'autotest de dépistage du VIH INSTI, aux membres de l'Association pharmaceutique du Kenya. bioLytical a été convié par la Clinton Health Access Initiative (CHAI) et la Kenya Pharmaceutical Association (KPA) à présenter l'autotest de dépistage du VIH INSTI à 350 représentants en pharmacie à Nairobi et à Mombasa, au Kenya. CHAI assure la coordination d'un projet d'auto-dépistage du VIH innovant qui vise à permettre aux pharmacies kenyanes de se doter en autotests VIH peu onéreux. L'autotest de dépistage du VIH INSTI est le seul autotest sanguin invité à intégrer le projet du fait de ses caractéristiques et de ses résultats hors du commun. Rick Galli, directeur technique de bioLytical, s'est rendu au Kenya pour y rencontrer des représentants de la KPA en prévision du lancement du programme. « En faisant entrer un kit d'auto-dépistage du VIH en Afrique subsaharienne par l'intermédiaire du secteur privé le Kenya montre la voie », a indiqué M. Galli. « bioLytical est ravi de prendre les devants de cette initiative révolutionnaire grâce à laquelle il sera possible de démontrer qu'un programme d'auto-dépistage du VIH peu onéreux et simple d'accès peut s'avérer efficace et permettre à chacun de prendre sa santé en main. » Grâce à cette nouvelle initiative à laquelle sont associées plus de 7 000 pharmacies réglementées dans tout le Kenya, les pharmacies locales, qui sont un maillon essentiel du réseau de santé, vont pouvoir proposer un test de dépistage du VIH à un prix abordable pour la majorité des Kenyans. Dans le cadre du programme d'auto-dépistage du VIH kenyan, des tests de dépistage du VIH à domicile seront distribués et un réseau de soutien et d'orientation vers des ressources de santé sera mis à la disposition de toute personne dont le test s'avère positif. Outil de dépistage de première intention, l'autotest de dépistage du VIH INSTI vise à identifier les personnes susceptibles d'avoir été contaminées par le VIH et à les inciter à se rendre le plus tôt possible dans un centre de soin pour y réaliser un test de confirmation et bénéficier de conseils en matière de prévention et de traitement. Pour les personnes dont le test est négatif, l'autotest est un moyen responsabilisant de rester maître de ses propres méthodes de prévention et de rester séronégatif. « Pour qu'un nouveau projet de ce type porte ses fruits, il est impératif qu'il prévoie des mises en relation et des conseils adaptés », souligne M. Galli. « Nous mettons tout en œuvre avec la CHAI, la KPA et d'autres parties prenantes au Kenya pour nous assurer que les personnes qui choisissent de recourir à l'autotest de dépistage du VIH INSTI sachent comment et où se faire aider après la réalisation du test. » bioLytical Laboratories Inc. est une entreprise canadienne privée, spécialisée dans la recherche, le développement et la commercialisation de tests de diagnostic in vitro rapides en centre de soins reposant sur sa plateforme technologique exclusive INSTI. Avec à son actif une série de certifications à l'échelle mondiale, comprenant notamment des homologations de l'agence américaine des produits alimentaires et médicamenteux (FDA), de Santé Canada et le marquage CE, bioLytical commercialise et vend son test VIH INSTI dans le monde entier et le test INSTI HIV/Syphilis Multiplex en Europe. La gamme INSTI produit des résultats de test extrêmement fiables en 60 secondes ou moins, ce qui s'avère beaucoup plus rapide que les tests concurrents basés sur une technologie de flux latéral, nécessitant généralement 15 à 20 minutes. bioLytical est doté d'un programme de R&D incluant des tests permettant de dépister des maladies telles que Zika, la dengue, le chikungunya, l'hépatite C et Ebola, entre autres. L'entreprise fournit aussi des services contractuels pour adapter la plateforme INSTI aux exigences fonctionnelles et techniques du dépistage personnalisé. Pour tout complément d'information, rendez-vous à la page http://www.biolytical.com.


News Article | December 2, 2016
Site: en.prnasia.com

RICHMOND, British Columbia, Dec. 2, 2016 /PRNewswire/ -- bioLytical Laboratories, a world leader in rapid infectious disease tests, introduced the Company's newest product, the INSTI HIV Self Test, to Kenya's Pharmaceutical Association members. bioLytical was invited by the Clinton Health Access Initiative (CHAI) and the Kenya Pharmaceutical Association (KPA) to introduce the INSTI HIV Self Test to 350 pharmacy representatives in Nairobi and Mombasa, Kenya.  CHAI has been coordinating an innovative HIV self-testing initiative aimed at bringing low cost HIV self-tests into pharmacies in Kenya.  The INSTI HIV Self Test was the only blood-based self-test invited to participate due to its unique features and performance characteristics. Rick Galli, bioLytical's Chief Technical Officer travelled to Kenya to meet with delegates of KPA in advance of this program launch.  "Kenya is leading the way in bringing HIV self-testing into sub-Saharan Africa through the private sector" said Galli. "bioLytical is excited to lead in this ground-breaking initiative that will demonstrate how a low cost, accessible HIV self-testing program can be effective and empowering for individuals to take control of their health". With a network of over 7,000 regulated pharmacies throughout Kenya, this new initiative will allow access to HIV testing that is affordable to most Kenyans across the country, through local pharmacies, which are a vital link in the healthcare network. The Kenyan HIV self-testing program will not only involve the distribution of home HIV tests, but will also include a network of support and linkage to care resources for any individuals who test positive.  As a first line screening tool, the INSTI HIV Self Test is intended to identify individuals who are likely to be HIV infected and instruct them to go to a clinic as soon as possible for confirmatory testing and counseling on prevention and treatment.  For those who test negative, self-testing is an empowering opportunity for individuals to take control of their prevention methods and remain HIV negative. "For a new program like this to be successful, it is vital that proper counselling and linkage aspects are soundly addressed" says Galli. "We are working with CHAI, KPA and other stakeholders in Kenya to ensure that individuals who choose to use the INSTI HIV Self Test are properly informed on how and where to access the support they need after testing." bioLytical Laboratories Inc. is a privately owned Canadian company engaged in the research, development and commercialization of rapid, point of care in vitro medical diagnostics using its proprietary INSTI technology platform.  With a world-wide footprint of regulatory approvals including US FDA approval, Health Canada approval and CE mark, bioLytical markets and sells its INSTI HIV test globally and INSTI HIV/Syphilis Multiplex test in Europe.  The INSTI product line provides highly accurate test results in 60 seconds or less, far faster than the 15-20 minutes required for competitors' tests based on lateral flow technology.  bioLytical has an active R&D program with a pipeline that includes tests for diseases such as Zika, Dengue, Chikungunya, Hepatitis C and Ebola, among others.  The company also provides contract services to adapt the INSTI platform to meet custom functional and technical diagnostic testing requirements.  For more information, please visit www.biolytical.com.


News Article | December 2, 2016
Site: www.prnewswire.co.uk

bioLytical Laboratories, un líder mundial en test rápidos de enfermedades infecciosas, presentó el nuevo producto de la Compañía, el INSTI HIV Self Test, a los miembros de la Kenya Pharmaceutical Association. bioLytical fue invitada por la Clinton Health Access Initiative (CHAI) y la Kenya Pharmaceutical Association (KPA) para presentar el INSTI HIV Self Test a 350 representantes farmacéuticos en Nairobi y Mombasa, Kenia. CHAI ha estado coordinando un autotest del VIH innovador orientado a aportar autotest de VIH de bajo coste a farmacias en Kenia. El INSTI HIV Self Test fue el único autotest sanguíneo invitado a participar debido a sus características únicas y características de rendimiento. Rick Galli, director técnico de bioLytical, viajó a Kenia para reunirse con delegados de KPA con antelación a este lanzamiento de programa. "Kenia está liderando el camino para llevar el autotest del VIH al África subsahariana a través del sector privado", dijo Galli. "bioLytical está encantado de liderar en esta revolucionaria iniciativa que demostrará como un programa de autotest del VIH accesible a bajo coste puede ser efectivo y permitir que las personas tengan el control sobre su salud". Con una red de más de 7.000 farmacias reguladas en Kenia, esta nueva iniciativa permitirá el acceso al test del VIH que sea asequible para la mayoría de los kenianos en el país, mediante farmacias locales, que son un enlace vital en la red sanitaria. El programa de autotest del VIH keniano no solo implicará la distribución de los test del VIH para uso en casa, sino que también incluirá una red de apoyo y conexión con los servicios de atención para las personas que den positivo. Como herramienta de exploración de primera línea, el INSTI HIV Self Test identificará a personas con probabilidad de estar infectadas por el VIH y las instruirá para ir a una clínica lo antes posible para realizar un test de confirmación y recibir asesoramiento sobre prevención y tratamiento. Para quienes den negativo, el autotest es una oportunidad de tener el control de sus métodos de prevención y seguir dando negativo en VIH. "Para que un nuevo programa como éste tenga éxito, es vital que se aborde sonadamente los aspectos adecuados de asesoramiento y conexión", dijo Galli. "Estamos trabajando con CHAI, KPA y otras partes implicadas en Kenia para asegurar que las personas que elijan utilizar el INSTI HIV Self Test sean adecuadamente informadas sobre cómo y dónde acceder al apoyo que necesitan una vez hecho el test". bioLytical Laboratories Inc. es una compañía canadiense de propiedad privada implicada en la investigación, desarrollo y comercialización de diagnósticos médicos rápidos e in vitro utilizando su plataforma de tecnología INSTI patentada. Con una huella mundial de aprobaciones regulatorias que incluyen la aprobación de la FDA de EE. UU., la aprobación de Health Canada y la Marca CE, bioLytical comercializa y vende su prueba para el VIH de INSTI globalmente y la prueba VIH/sífilis multiplex de INSTI en Europa. La línea de productos INSTI ofrece resultados de pruebas altamente precisos en 60 segundos o menos, mucho más rápido de 15-20 minutos requeridos por las pruebas para competidores basadas en la tecnología de flujo lateral. bioLytical tiene un programa de I+D activo con una línea que incluye pruebas para enfermedades como el Zika, Dengue, Chikungunya, Hepatitis C y Ébola, entre otras. La compañía también ofrece servicios contractuales para adaptar la plataforma INSTI para cubrir los requisitos de pruebas de diagnóstico técnicos y funcionales personalizados. Para más información, visite http://www.biolytical.com


News Article | December 2, 2016
Site: www.prnewswire.co.uk

bioLytical Laboratories, a world leader in rapid infectious disease tests, introduced the Company's newest product, the INSTI HIV Self Test, to Kenya's Pharmaceutical Association members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical was invited by the Clinton Health Access Initiative (CHAI) and the Kenya Pharmaceutical Association (KPA) to introduce the INSTI HIV Self Test to 350 pharmacy representatives in Nairobi and Mombasa, Kenya. CHAI has been coordinating an innovative HIV self-testing initiative aimed at bringing low cost HIV self-tests into pharmacies in Kenya. The INSTI HIV Self Test was the only blood-based self-test invited to participate due to its unique features and performance characteristics. Rick Galli, bioLytical's Chief Technical Officer travelled to Kenya to meet with delegates of KPA in advance of this program launch. "Kenya is leading the way in bringing HIV self-testing into sub-Saharan Africa through the private sector," said Galli. "bioLytical is excited to lead in this ground-breaking initiative that will demonstrate how a low cost, accessible HIV self-testing program can be effective and empowering for individuals to take control of their health." With a network of over 7,000 regulated pharmacies throughout Kenya, this new initiative will allow access to HIV testing that is affordable to most Kenyans across the country, through local pharmacies, which are a vital link in the healthcare network. The Kenyan HIV self-testing program will not only involve the distribution of home HIV tests, but will also include a network of support and linkage to care resources for any individuals who test positive. As a first line screening tool, the INSTI HIV Self Test is intended to identify individuals who are likely to be HIV infected and instruct them to go to a clinic as soon as possible for confirmatory testing and counseling on prevention and treatment. For those who test negative, self-testing is an empowering opportunity for individuals to take control of their prevention methods and remain HIV negative. "For a new program like this to be successful, it is vital that proper counselling and linkage aspects are soundly addressed," says Galli. "We are working with CHAI, KPA and other stakeholders in Kenya to ensure that individuals who choose to use the INSTI HIV Self Test are properly informed on how and where to access the support they need after testing." bioLytical Laboratories Inc. is a privately owned Canadian company engaged in the research, development and commercialization of rapid, point of care in vitro medical diagnostics using its proprietary INSTI technology platform. With a world-wide footprint of regulatory approvals including US FDA approval, Health Canada approval and CE mark, bioLytical markets and sells its INSTI HIV test globally and INSTI HIV/Syphilis Multiplex test in Europe. The INSTI product line provides highly accurate test results in 60 seconds or less, far faster than the 15-20 minutes required for competitors' tests based on lateral flow technology. bioLytical has an active R&D program with a pipeline that includes tests for diseases such as Zika, Dengue, Chikungunya, Hepatitis C and Ebola, among others. The company also provides contract services to adapt the INSTI platform to meet custom functional and technical diagnostic testing requirements. For more information, please visit http://www.biolytical.com.


Gill C.J.,Boston University | Young M.,UNICEF | Schroder K.,Clinton Health Access Initiative | Carvajal-Velez L.,UNICEF | And 4 more authors.
The Lancet | Year: 2013

Millions of children still die unnecessarily from pneumonia and diarrhoea, mainly in resource-poor settings. A series of collaborative consultations and workshops involving several hundred academic, public health, governmental and private sector stakeholders were convened to identify the key barriers to progress and to issue recommendations. Bottlenecks impairing access to commodities included antiquated supply management systems, insufficient funding for drugs, inadequate knowledge about interventions by clients and providers, health worker shortages, poor support for training or retention of health workers, and a failure to convert national policies into action plans. Key programmatic barriers included an absence of effective programme coordination between and within partner organisations, scarce financial resources, inadequate training and support for health workers, sporadic availability of key commodities, and suboptimal programme management. However, these problems are solvable. Advocacy could help to mobilise needed resources, raise awareness, and prioritise childhood pneumonia and diarrhoea deaths in the coming decade. © 2013 Elsevier Ltd.

Loading Clinton Health Access Initiative collaborators
Loading Clinton Health Access Initiative collaborators